These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 26297254)

  • 1. Dual NRASQ61R and BRAFV600E mutation-specific immunohistochemistry completes molecular screening in melanoma samples in a routine practice.
    Uguen A; Guéguen P; Legoupil D; Bouvier S; Costa S; Duigou S; Lemasson G; Ledé F; Sassolas B; Talagas M; Férec C; Le Maréchal C; De Braekeleer M; Marcorelles P
    Hum Pathol; 2015 Nov; 46(11):1582-91. PubMed ID: 26297254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of a Rapid, Fully Automated Platform for Detection of BRAF and NRAS Mutations in Melanoma.
    Barel F; Guibourg B; Lambros L; Le Flahec G; Marcorelles P; Uguen A
    Acta Derm Venereol; 2018 Jan; 98(1):44-49. PubMed ID: 28660280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.
    Uguen A; Talagas M; Costa S; Samaison L; Paule L; Alavi Z; De Braekeleer M; Le Marechal C; Marcorelles P
    Diagn Pathol; 2015 Jul; 10():121. PubMed ID: 26204954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemistry is highly sensitive and specific for the detection of NRASQ61R mutation in melanoma.
    Massi D; Simi L; Sensi E; Baroni G; Xue G; Scatena C; Caldarella A; Pinzani P; Fontanini G; Carobbio A; Urso C; Mandalà M
    Mod Pathol; 2015 Apr; 28(4):487-97. PubMed ID: 25341653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accurate detection of BRAF p.V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular assays.
    Fisher KE; Cohen C; Siddiqui MT; Palma JF; Lipford EH; Longshore JW
    Hum Pathol; 2014 Nov; 45(11):2281-93. PubMed ID: 25228337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunohistochemistry using clone VE1 is an economic, specific and sensitive method for detecting the presence of BRAFV600E mutations in melanoma].
    Etienne M; Oca F; Prunier-Mirebeau D; Croué A; Martin L
    Ann Dermatol Venereol; 2018 Mar; 145(3):159-165. PubMed ID: 29221650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting.
    Kakavand H; Walker E; Lum T; Wilmott JS; Selinger CI; Smith E; Saw RP; Yu B; Cooper WA; Long GV; O'Toole SA; Scolyer RA
    Histopathology; 2016 Oct; 69(4):680-6. PubMed ID: 27151331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
    Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
    Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay.
    Vallée A; Denis-Musquer M; Herbreteau G; Théoleyre S; Bossard C; Denis MG
    PLoS One; 2019; 14(8):e0221123. PubMed ID: 31415669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Why and how immunohistochemistry should now be used to screen for the BRAFV600E status in metastatic melanoma? The experience of a single institution (LCEP, Nice, France).
    Long E; Ilie M; Lassalle S; Butori C; Poissonnet G; Washetine K; Mouroux J; Lespinet V; Lacour JP; Taly V; Laurent-Puig P; Bahadoran P; Hofman V; Hofman P
    J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2436-43. PubMed ID: 26377147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between BRAFV600E and NRASQ61R mutations and clinicopathologic characteristics, risk factors and clinical outcome of primary invasive cutaneous melanoma.
    Wu S; Kuo H; Li WQ; Canales AL; Han J; Qureshi AA
    Cancer Causes Control; 2014 Oct; 25(10):1379-86. PubMed ID: 25048604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF, NRAS, and GNAQ Mutations in Conjunctival Melanocytic Nevi.
    Francis JH; Grossniklaus HE; Habib LA; Marr B; Abramson DH; Busam KJ
    Invest Ophthalmol Vis Sci; 2018 Jan; 59(1):117-121. PubMed ID: 29332123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NRASQ61R immunohistochemistry detects both NRASQ61R and KRASQ61R mutations in colorectal cancer.
    Jhuang JY; Yuan CT; Lin YL; Cheng ML; Liau JY; Tsai JH
    Pathology; 2017 Jun; 49(4):387-390. PubMed ID: 28433252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative analysis of BRAF, NRAS and c-KIT mutation status between tumor tissues and autologous tumor cell-lines of stage III/IV melanoma.
    Knol AC; Pandolfino MC; Vallée A; Nguyen F; Lella V; Khammari A; Denis M; Puaux AL; Dréno B
    Exp Dermatol; 2015 Jan; 24(1):70-3. PubMed ID: 25363723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.
    Long GV; Wilmott JS; Capper D; Preusser M; Zhang YE; Thompson JF; Kefford RF; von Deimling A; Scolyer RA
    Am J Surg Pathol; 2013 Jan; 37(1):61-5. PubMed ID: 23026937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemistry as a potential tool for routine detection of the NRAS Q61R mutation in patients with metastatic melanoma.
    Ilie M; Long-Mira E; Funck-Brentano E; Lassalle S; Butori C; Lespinet-Fabre V; Bordone O; Gay A; Zahaf K; Poissonnet G; Lacour JP; Bahadoran P; Ballotti R; Gros A; Dutriaux C; Saiag P; Merlio JP; Vergier B; Emile JF; Hofman V; Hofman P
    J Am Acad Dermatol; 2015 May; 72(5):786-93. PubMed ID: 25659223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NRASQ61R Mutation-specific Immunohistochemistry is Highly Specific for Either NRASQ61R or KRASQ61R Mutation in Colorectal Carcinoma.
    Turchini J; Andrici J; Sioson L; Clarkson A; Watson N; Toon CW; Shepherd P; Ng D; Dixon-McIver A; Oei P; Gill AJ
    Appl Immunohistochem Mol Morphol; 2017 Aug; 25(7):475-480. PubMed ID: 26862952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAFV600E protein expression in primary cutaneous malignant melanomas and paired metastases.
    Eriksson H; Zebary A; Vassilaki I; Omholt K; Ghaderi M; Hansson J
    JAMA Dermatol; 2015 Apr; 151(4):410-6. PubMed ID: 25588152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma.
    Sensi M; Nicolini G; Petti C; Bersani I; Lozupone F; Molla A; Vegetti C; Nonaka D; Mortarini R; Parmiani G; Fais S; Anichini A
    Oncogene; 2006 Jun; 25(24):3357-64. PubMed ID: 16462768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-reactivity of NRASQ61R antibody in a subset of Spitz nevi with 11p gain: a potential confounding factor in the era of pathway-based diagnostic approach.
    Parra O; Lefferts JA; Tafe LJ; Gru AA; Linos K
    Hum Pathol; 2021 Jun; 112():35-47. PubMed ID: 33636207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.